Navigation Links
CytoSorbents to Report Q2 2014 Operating and Financial Results
Date:8/6/2014

MONMOUTH JUNCTION, N.J., Aug. 6, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q2 2014 financial results after the market close on Tuesday, August 12, 2014. 

CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q2 2014 and answer pre-submitted questions as time permits.

Conference Call Details:
Date: Tuesday, August 12, 2014
Time: 4:15 PM Eastern
Participant Dial-In: 913-312-1269
Live Presentation Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1041083

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.  There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link:  https://viavid.webcasts.com/starthere.jsp?ei=1041083

An archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://www.cytosorbents.com/invest.htm

Investors are encouraged to submit their questions in advance as soon as possible to Ms. Amy Vogel at avogel@cytosorbents.com

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.

Please Click to Follow us on Facebook and Twitter

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO


'/>"/>
SOURCE CytoSorbents Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. MedReps.com Report Highlights Power of Mobile Medical Sales Job Search
2. 2-EH Market & Linear Alkyl Benzene Industry – Global, China Regions Research Analysis Now Available at DeepResearchReports.com
3. PharmAthene Reports Second Quarter 2014 Financial And Operational Results
4. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2014
5. Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com
6. Cambrex Reports Second Quarter 2014 Financial Results
7. Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com
8. BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014
9. Kidney Cancer Association Joins CNN iReport
10. China Diagnostic Reagent Industry Report, 2013-2016
11. Researchmoz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... WuXi Biologics, a leading open-access R&D ... and a WuXi AppTec Affiliate, today announced that ... Excellence Award from IMAPAC, a leading consulting firm. ... recognize outstanding leaders and trend-setters of today, and ... biomanufacturing experts in the industry, along with the ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Agricultural Chelates ... over the next decade to reach approximately $825.4 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/29/2017)... , March 29, 2017 The Global Microfluidic ... report is a specialized and comprehensive study on the existing state ... America , Europe and ... Middle East and Africa . ... Browse 172 Tables and ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):